Krilogy Financial’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$375K Sell
1,729
-335
-16% -$82.8K 0.01% 766
2026
Q2
$497K Buy
+2,064
New +$452K 0.01% 635
2018
Q4
– Sell
-585
Closed -$98K – 410
2018
Q3
$98K Buy
+585
New +$101K 0.02% 223
2018
Q2
– Sell
-975
Closed -$147K – 396
2018
Q1
$147K Sell
975
-50
-5% -$7.34K 0.04% 181
2017
Q4
$138K Hold
1,025
– – 0.03% 183
2017
Q3
$150K Sell
1,025
-575
-36% -$87K 0.04% 195
2017
Q2
$249K Sell
1,600
-1,300
-45% -$199K 0.07% 121
2017
Q1
$316K Hold
2,900
– – 0.1% 93
2016
Q4
$316K Sell
2,900
-250
-8% -$27.8K 0.1% 93
2016
Q3
$383K Sell
3,150
-100
-3% -$13.5K 0.12% 82
2016
Q2
$459K Sell
3,250
-100
-3% -$14.7K 0.16% 73
2016
Q1
$437K Sell
3,350
-500
-13% -$62.2K 0.18% 58
2015
Q4
$541K Sell
3,850
-50
-1% -$6.93K 0.5% 29
2015
Q3
$518K Buy
+3,900
New +$672K 0.25% 50

Other funds holding JAZZ

Krilogy Financial's JAZZ Position: Q3 2026 in Review

Krilogy Financial reduced its Jazz Pharmaceuticals (JAZZ) stake by 16% in Q3 2026, selling an estimated $82.8K and leaving 1,729 shares worth $375K. The position accounts for 0.01% of the portfolio, ranked #766.

Krilogy Financial first reported a position in JAZZ in Q3 2015 and has held it in 14 quarters since. The position peaked at $541K in Q4 2015. 669 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Krilogy Financial held 1,729 shares of Jazz Pharmaceuticals worth $375K as of Q3 2026.
  • Krilogy Financial sold 335 Jazz Pharmaceuticals shares in Q3 2026, an estimated $82.8K.
  • Jazz Pharmaceuticals made up 0.01% of Krilogy Financial's portfolio in Q3 2026, its #766 holding.
  • Krilogy Financial first reported a position in Jazz Pharmaceuticals in Q3 2015 and has held it in 14 quarters since.
  • Krilogy Financial's Jazz Pharmaceuticals position peaked at $541K in Q4 2015.
  • 669 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Krilogy Financial's 13F filing for Q3 2026, filed 13 Oct 2026.